Table 2 Adverse effects according to the treatment group (any grade).
Arm A | Arm B | p value | |
|---|---|---|---|
n (%) | N (%) | ||
Decreased EF during treatment | 3 (6.0) | 11 (12.0) | 0.37 |
EF decrease rate | 0.50 | ||
0–10% | 3 (6.0) | 9 (9.8) | |
11–20% | 0 (0.0) | 2 (2.2) | |
EF decrease (asymptomatic) | 3 (6.0) | 11 (12.0) | 0.37 |
Anemia | 33 (66.0) | 54 (58.7) | 0.39 |
Thrombocytopenia | 27 (54.0) | 28 (30.4) | 0.006a |
Lokopenia | 35 (70.0) | 51 (55.4) | 0.09 |
Neutropenia | 35 (70.0) | 60 (65.2) | 0.56 |
Nausea | 39 (78.0) | 76 (82.6) | 0.50 |
Vomiting | 27 (54.0) | 58 (63.0) | 0.29 |
Mucositis | 26 (52.0) | 32 (34.8) | 0.04a |
Fatigue | 46 (92.0) | 81 (88.0) | 0.46 |
Diarrhea | 18 (36.0) | 32 (34.8) | 0.88 |
Rash | 10 (20.0) | 18 (19.6) | 0.95 |
Allergy and anaphylaxis | 5 (10.0) | 7 (7.6) | 0.75 |
Hepatotoxicity | 6 (12.0) | 16 (17.4) | 0.39 |
Neuropathy | 24 (48.0) | 46 (50.0) | 0.82 |
Febrile neutropenia | 2 (4.0) | 1 (1.1) | 0.28 |
Toxicity-induced dose reduction | 9 (18.0) | 11 (12.0) | 0.32 |
Hospitalization due to toxicity | 8 (16.0) | 15 (16.3) | 0.96 |
